West Pharma officer exercises RSUs, withholds shares

West Pharmaceutical Services VP and Chief Accounting Officer Chad Winters exercised restricted stock units into common stock and had shares withheld to cover taxes.

Rhea-AI Filing Summary

West Pharmaceutical Services VP and Chief Accounting Officer Chad Winters exercised restricted stock units into common stock and had shares withheld to cover taxes. On February 20, 2026, he converted 89.328 restricted stock units into the same number of common shares at $0.00 per share, increasing his direct common stock holdings to 1,552.994 shares. On the same date, 30.184 common shares were disposed of at $241.12 per share in a tax-withholding transaction, leaving him with 1,522.810 common shares directly owned. Footnotes state these restricted stock units convert to common stock on a one-for-one basis and relate to a prior grant that vests in four equal annual installments.

Insider Trade Summary

89.328 shares exercised/converted

Exercise 3 txns

Insider Winters Chad

Role VP, Chief Accounting Officer

Type	Security	Shares	Price	Value
Exercise	Rst. Stock Unit	89.328	$0.00	$0.00
Exercise	Common Stock	89.328	$0.00	$0.00
Exercise Price or Tax Liability	Common Stock	30.184	$241.12	$7K

Holdings After Transaction: Rst. Stock Unit — 267.972 contracts (Direct); Common Stock — 1,522.81 shares (Direct)

Footnotes (2)

1. F1. Restricted stock units convert into common stock on a one-for-one basis.
2. F2. On February 18, 2025, the reporting person was granted 356 restricted stock units, vesting in four equal annual installments (plus dividend equivalents) on February 20th each year.

FAQ

What insider transactions did WST executive Chad Winters report on this Form 4?

Chad Winters reported exercising 89.328 restricted stock units into common stock and a disposition of 30.184 common shares for tax withholding, all dated February 20, 2026, reflecting routine equity compensation activity.

Did Chad Winters of WST buy or sell shares on the open market?

The Form 4 shows no open-market purchases or sales. It reports a derivative exercise of restricted stock units and a tax-withholding disposition, where shares are surrendered to cover tax liabilities from the equity award.

How many West Pharmaceutical (WST) common shares does Chad Winters own after these transactions?

After the reported transactions, Chad Winters directly owns 1,522.810 common shares. This figure reflects the conversion of restricted stock units into shares and the subsequent tax-withholding share disposition on February 20, 2026.

What restricted stock unit activity did WST disclose for Chad Winters?

Winters converted 89.328 restricted stock units into an equal number of common shares. Footnotes explain restricted stock units convert to common stock on a one-for-one basis, tied to a prior grant that vests annually over four years.

Why were 30.184 West Pharmaceutical (WST) shares disposed of in Chad Winters’ Form 4?

The 30.184 common shares were disposed of at $241.12 per share in a tax-withholding transaction. Such dispositions occur when shares are surrendered to satisfy tax obligations arising from equity award vesting or exercise.

What does the prior restricted stock unit grant to WST executive Chad Winters involve?

A prior grant awarded 356 restricted stock units on February 18, 2025, vesting in four equal annual installments on February 20 each year, with dividend equivalents. As units vest, they convert one-for-one into West Pharmaceutical common stock.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/23/2026 - 05:40 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Winters Chad

(Last) (First) (Middle)

530 HERMAN O. WEST DRIVE

(Street)

EXTON PA 19341

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
WEST PHARMACEUTICAL SERVICES INC [ WST ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	VP, Chief Accounting Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/20/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/20/2026		M		89.328	A	(1)	1,552.994	D
Common Stock	02/20/2026		F		30.184	D	$241.12	1,522.81	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Rst. Stock Unit	(1)	02/20/2026		M			89.328	(2)	(2)	Common Stock	89.328	$0	267.972	D

Explanation of Responses:

1. Restricted stock units convert into common stock on a one-for-one basis.

2. On February 18, 2025, the reporting person was granted 356 restricted stock units, vesting in four equal annual installments (plus dividend equivalents) on February 20th each year.

	/s/ Louis Lalli, as an agent for Chad Winters	02/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.